• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Investigation of the treatment for gastrointestinal cancers and gastrointestinal stromal tumors using the glucose transporter 1 inhibitor.

Research Project

  • PDF
Project/Area Number 19K09199
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 55020:Digestive surgery-related
Research InstitutionKumamoto University

Principal Investigator

Sawayama Hiroshi  熊本大学, 病院, 助教 (40594875)

Co-Investigator(Kenkyū-buntansha) 石本 崇胤  熊本大学, 病院, 特任准教授 (00594889)
清住 雄希  熊本大学, 病院, 非常勤診療医師 (30827324)
岩槻 政晃  熊本大学, 大学院生命科学研究部(医), 助教 (50452777)
宮本 裕士  熊本大学, 病院, 講師 (80551259)
Project Period (FY) 2019-04-01 – 2022-03-31
Keywords消化管癌 / GIST / 抗癌剤感受性 / GLUT1阻害剤 / BAY-876
Outline of Final Research Achievements

Cancer growth is reported to be dependent on glucose metabolism. We demonstrated that suppressing the expression of glucose transporter 1 (GLUT1), which is responsible for glucose uptake into cancer cells, had an inhibitory effect on proliferation in esophageal cancer cell lines. The expression of GLUT1 was associated with the sensitivity to cisplatin, a platinum-based anti-cancer drug, and suppressing GLUT1 expression improved the sensitivity to the anti-cancer drug. BAY-876, a specific inhibitor for GLUT1 at low concentrations, inhibited cell proliferation and had an additive effect with cisplatin. The expression of GLUT1 was associated with the therapeutic effect of anticancer drugs, in clinical specimens of esophageal squamous cell carcinoma.

Free Research Field

癌特異的な糖代謝に対する低分子化合物を用いた抗がん剤感受性、抗腫瘍効果に関する研究

Academic Significance and Societal Importance of the Research Achievements

抗癌剤治療において抗癌剤耐性機序の解明は重要な課題である。また、細胞障害性抗癌剤やがん遺伝子に対する分子標的療法が治療の中心であり新たな治療法の開発が望まれる。我々は、癌の糖代謝経路に関係するGLUT1が抗癌剤感受性の関係することを明らかにした。さらに、低濃度で作用するGLUT1阻害剤を用い、食道扁平上皮癌の増殖抑制効果を示した。本研究によって、抗癌剤感受性に関係する因子が明らかになり、糖代謝経路を標的とした新たな治療法の可能性を示した。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi